Shilpa Medicare gets warning letter from USFDA for Jadcherla facility

12 Oct 2020 Evaluate

Shilpa Medicare has received a warning letter from US Food and Drug Administration (USFDA) for its Jadcherla facility, Telangana. The warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility. The company is also committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities.

The company currently has three manufacturing facilities approved by USFDA - one formulation facility and two API facilities. None of these facilities except Jadcherla has any outstanding issues with the USFDA at this point of time.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

323.60 -7.70 (-2.32%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×